Press Releases
 
New compound could improve stroke patient recovery

A new compound shows promise for improving motor function recovery for stroke patients in combination with rehabilitation therapy. Human clinical trials for a new drug are underway.

YOKOHAMA, Japan, 11 April 2018 -- (ACN Newswire) -- A team of Japanese researchers have developed a new compound that enhanced motor function recovery after brain damage in animal tests, according to a study published in the journal Science.

The small-molecule compound, called edonerpic maleate, was developed by a research team led by Yokohama City University and Toyama Chemical Co., Ltd. in Japan. When administered to rodents and monkeys undergoing rehabilitation for brain damage, both groups of animals showed greater and faster recovery of motor function than those with just rehabilitation alone.

Toyama Chemical has already completed a clinical trial for the drug in healthy people, and plans to next conduct a clinical trial with stroke patients. The Phase 2 trial is expected to evaluate the drug's safety and ability to accelerate rehabilitation in humans. The drug must complete three phases of successful trials before it can be approved as a medication.

More than 17 million people worldwide suffer from strokes each year. The majority of strokes block blood flow to the brain, which can lead to severe paralysis. Loss of function depends on the size and location of the affected area. Some available treatments are limited to the few hours following a stroke. Long-term treatment often involves different types of physical therapy, and motor function recovery varies from patient to patient.

In this new study, the researchers describe how edonerpic maleate helps accelerate recovery of motor function. For example, macaque monkeys doing physical therapy and receiving edonerpic maleate were able to pinch small food with their fingers within a month of starting treatment. Recovery of such fine motor movements is often difficult for stroke patients.

"I hope this drug will help a lot of patients who suffer from paralysis after stroke," said Professor Takuya Takahashi, of Yokohama City University Graduate School of Medicine, who led the research.

Notably, the small-molecule compound shows positive results even when treatment started a month after the induction of brain damage - not just hours. This has the potential to boost recovery prospects for many stroke patients.

The compound appears to work in tandem with rehabilitation to enhance neural plasticity. Neural plasticity is the brain's ability to learn and adapt in response to experience. Brain cells affected by stroke cease to function normally within seconds of the trauma. However, the brain can create new pathways between neurons with external stimuli, in this case, physical rehabilitation - this is the essence of neural plasticity.

Edonerpic maleate helps this process by facilitating the delivery of an important neurotransmitter receptor, called AMPA receptor, to the structures called synapses, which mediate information between neurons. The AMPA receptors are very important for signal transmission and information processing. They receive signals from glutamate, a major neurotransmitter, and help transmit the glutamate signal to the next neuron. By helping build up AMPA receptors at synapses in conjunction with rehabilitative training, edonerpic maleate helps increase the potential for a signal transmission and neuron response.

The researchers further determined that edonerpic maleate works by binding to an intracellular protein called collapsin-response-mediator-protein 2 (CRMP2), which is related to synaptic plasticity. Mice lacking CRMP2 protein did not show an increase in AMPA receptors nor recovery of motor function, even with edonerpic maleate, indicating that CRMP2 is critical for the compound to work.

The research was done in collaboration with Japan's National Institute of Advanced Industrial Science and Technology, and the National Institutes of Biomedical Innovation, Health, and Nutrition.

Journal Reference:
Abe, H. et al. "CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage." Science April 6, 2018 Vol. 360, Issue 6384, pp. 50-57 DOI: 10.1126/science.aao2300

Media Contacts:
Makoto Watanabe
Supervisor, Research Planning and University-Industry Cooperation Division
Yokohama City University
E-Mail:

Toyama Chemical Co., Ltd.
General Affairs and Personnel Department
E-Mail:

About Yokohama City University:
Located in the international city of Yokohama, Yokohama City University has 4 campuses, 3 faculties, 5 graduate schools, 2 affiliated research centers, and 2 affiliated hospitals that serve as the bases for education, research, and medical care. Specifically, medical science research is led by the Advanced Medical Research Center. Additional information about Yokohama City University is available through its website at: https://www.yokohama-cu.ac.jp/en/

# # #


Submitted by ACN Newswire, ACN Newswire on Wednesday, 11 April 2018 at 5:46 PM
Category: Science & Research
 
Related News

2023 Global CBCT Dental Imaging Market: Analysis, Modeling, Risk Factors, Growth Strategies, Drivers
Wednesday, 18 Apr 2018

Liquid Biopsy Global Market: Segmentation and Analysis by Recent Trends, Development and Growth by R
Monday, 16 Apr 2018

Global Vaccine Technologies Market: Size, Share, Growth, Analysis & Demand 2022
Saturday, 14 Apr 2018

Tree Services by Denver Tree Trimming Company Helps Wildlife Habitats
Friday, 13 Apr 2018

Global Phototherapy System Market: Analysis by Key Players, Industry Growth, Size, Share, Trends, Sa
Wednesday, 11 Apr 2018

Related Events

Military Space Situational Awareness 2018
Wednesday, 25 Apr 2018

Palo Alto Networks: Virtual Ultimate Test Drive - Advanced Endpoint Protection - JUN 19, 2018
Tuesday, 19 Jun 2018

Disruptive Sustainability Technologies Conference
Wednesday, 18 Jul 2018

Latest News

Pecan Oil Market Forecast Research Reports Offers Key Insights
Thursday, 26 Apr 2018

Global Reprocessed Medical Devices Market to Reach Worth USD 2,461.4 Mn by 2022
Thursday, 26 Apr 2018

Fracture Fixation Products Market Key Drivers & On-going Trends 2016 - 2024
Thursday, 26 Apr 2018

Laboratory Sterilizers Market Insights by Size, Status and Forecast 2023
Thursday, 26 Apr 2018

Maca Powder Market To Increase at Steady Growth Rate
Thursday, 26 Apr 2018

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Thursday, 26 April 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • ChinaBio Partnering Forum, Suzhou 2018
  • Stoller: A Comprehensive Tutorial in Musculoskeletal Imaging
  • Military Space Situational Awareness 2018
  • INTERCHARM Professional
  • Advantages of portable jaw crusher plant

  • Latest Jobs
    Sorry, there are currently no entries posted here.